Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study [0.03%]
肿瘤浸润淋巴细胞及促炎症生物标志物与乳腺癌分子亚型的相关性：来自MEND研究的分析结果
Jovita Byemerwa,Drew Neish,Lukeman Forgah et al.
Jovita Byemerwa et al.
Purpose: Tumor-infiltrating lymphocytes (TILs) and proinflammatory biomarkers shape breast cancer (BC) progression and outcomes. We estimated the association between TILs and BC subtypes in Nigerian women and, in explorat...
Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer [0.03%]
非骨寡转移性乳腺癌的根治性立体定向消融放疗、手术和全身治疗
Adhar Amritt,Abhilash Dagar,Adrija Ghosh et al.
Adhar Amritt et al.
Background: Stereotactic ablative body radiation (SABR), combined with systemic therapy (ST), is increasingly used to improve survival in oligometastatic breast cancer (OMBC). ...
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study [0.03%]
新辅助化疗免疫治疗后三阴性乳腺癌转移复发一线系统抗肿瘤治疗失败的单中心真实世界研究
Palma Fedele,Alessandro Rizzo,Matteo Landriscina et al.
Palma Fedele et al.
Purpose: To assess the incidence and determinants of early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer (TNBC) treated with neoadjuvant chemo-immunother...
Multicenter Study
Breast cancer research and treatment. 2026 Jul 10;218(1):8. DOI:10.1007/s10549-026-08023-2 2026
Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk [0.03%]
携带中等风险基因致病性变异或乳腺癌经验性风险增加的女性多基因检测后的乳腺癌筛查依从性
Jacob G Comeaux,Natalia Gutierrez,Charité N Ricker et al.
Jacob G Comeaux et al.
Purpose: To identify factors associated with adherence to breast cancer (BC) screening among women with a pathogenic or likely pathogenic (P/LP) variant in a moderate-risk gene, ATM, BARD1, CHEK2, RAD51C, and RAD51D or wi...
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study [0.03%]
绝经后ER阳性HER2阴性晚期乳腺癌患者内分泌治疗+CDK4/6抑制剂进展后的Everolimus疗效：EVERGREEN研究
Diogo Martins-Branco,Soraia Lobo-Martins,Philippe Aftimos et al.
Diogo Martins-Branco et al.
Purpose: There is limited evidence supporting the addition of everolimus to endocrine therapy in women with ER-positive/HER2-negative advanced breast cancer disease progression on CDK4/6 inhibitors. We aimed to assess the...
Multicenter Study
Breast cancer research and treatment. 2026 Jul 10;218(1):7. DOI:10.1007/s10549-026-08012-5 2026
Socioeconomic variation in adherence to follow-up after an abnormal screening mammogram in the Danish breast cancer screening program [0.03%]
丹麦乳腺癌筛查项目中异常乳房X线照片筛查后的随访依从性的社会经济差异
C M B Lundorff,S H Njor,S L Madsen et al.
C M B Lundorff et al.
Objectives: Timely and guideline-consistent follow-up after abnormal mammography findings is essential for early diagnosis and improved breast cancer outcomes. While socioeconomic position (SEP) is known to affect partici...
Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer [0.03%]
三维乳腺摄影与数字化乳腺摄影在老年女性中发现的乳腺癌的肿瘤特征差异研究
Sida Huang,Sarah J Westvold,Pamela R Soulos et al.
Sida Huang et al.
Background: Digital breast tomosynthesis (DBT) has demonstrated improved cancer detection compared with digital mammography (DM) in trials of women aged 50-74, identifying more invasive cancers and detecting tumors at sma...
mRNA and protein expression of fetal insulin receptor in breast cancer cell lines and tissues [0.03%]
人乳腺癌细胞系和组织中胎儿胰岛素受体的mRNA和蛋白质表达水平
Xihong Zhang,Albert Barrios,LeeAnn Higgins et al.
Xihong Zhang et al.
Background: The insulin receptor (IR) is expressed in breast cancer cells and plays a role in regulating tumor biology. There are two IR isoforms generated from the same gene. Alternate splicing with exclusion or inclusio...
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD [0.03%]
马来酸厄洛替尼与多西他赛或紫杉醇联合曲妥珠单抗和帕妥珠单抗一线治疗HER2阳性局部晚期或转移性乳腺癌的疗效和安全性：日本乳腺癌研究组- M06 / EMERALD亚组分析更新
Norikazu Masuda,Shigehira Saji,Yasuyuki Kojima et al.
Norikazu Masuda et al.
Purpose: We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribulin (E) vs. either docetaxel (DTX) or paclitaxel (PTX). ...
SERENA-6 and the regulatory limits of radiologic progression in modern oncology [0.03%]
SERENA-6和现代肿瘤学放射学进展的监管限度
Saeed Rafii,Humaid O Al-Shamsi,Adam Brufsky
Saeed Rafii
Background: The emergence of real-time molecular monitoring has challenged traditional oncology paradigms, where radiologic progression has historically represented the primary trigger for therapeutic intervention. The SE...